表紙
市場調查報告書

乾癬性關節炎 (PA) :競爭情形

Psoriatic Arthritis: Competitive Landscape to 2026

出版商 GlobalData 商品編碼 778083
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
乾癬性關節炎 (PA) :競爭情形 Psoriatic Arthritis: Competitive Landscape to 2026
出版日期: 2018年12月19日內容資訊: 英文 48 Pages
簡介

乾癬性關節炎 (PA) 治療藥市場,也可利用皮下治療和靜脈內治療,也包含低分子口服藥和生物相似藥,競爭日益變得激烈。

本報告提供乾癬性關節炎 (PA) 治療藥調查分析,開發平台的評估,臨床實驗的評估,商業性的評估,競爭情形分析相關的系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 開發平台的評估

  • 開發平台概要
  • 開發平台的明細:各地區/國家
  • 開發平台的明細:各分子類型、標的
  • 指定核准
  • 初期的臨床開發中的產品

第5章 臨床實驗的評估

  • 臨床實驗概要
  • 臨床實驗的主要贊助商
  • 臨床實驗的明細:各地區
  • 治療領域預測
  • 病患註冊

第6章 商業性的評估

  • 主要上市產品
  • 現在、未來的企業

第7章 競爭情形分析

  • 活動分類概要
  • 美國
  • EU5個國家
  • 日本
  • 澳洲

第8章 附錄

目錄
Product Code: GDHC019CL

The Psoriatic Arthritis (PsA) market has become increasingly competitive, with both subcutaneous and intravenous therapies being available as well as two oral small molecule and biosimilars. However, J&J and AbbVie are slated to remain headliners in the psoriatic arthritis marketplace, looking to capitalize on the excitement surrounding interleukin inhibitors and janus kinase inhibitors.

J&J and AbbVie have been the dominant players in the psoriatic arthritis market since the introduction of Remicade (2004) and Humira (2005) as the second and third TNF inhibitors approved by the FDA, respectively. AbbVie and J&J have launched or are developing biologics with novel mechanisms of action, including interleukin inhibitors, maintaining their position in the psoriatic arthritis space.

Diagnosed prevalence cases of psoriatic arthritis is expected to grow across each of the 8MM (United States, Japan, Australia, United Kingdom, France, Italy, Germany, Spain). The US will have the largest growth with almost 470,000 diagnosed prevalent cases in 2016, growing at an AGR of 5.36% to 2026.

It is found that industry sponsors are responsible for over 70% of psoriatic arthritis clinical trials, with the top seven industry sponsors accounting for 64% of all industry sponsored trials. Of these AbbVie and Johnson & Johnson (J&J) are responsible for 47 of the 121 industry sponsored clinical trials in the psoriatic arthritis space.

The report "Psoriatic Arthritis: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of psoriatic arthritis. Overall, it is expected that new drug approvals to drive market growth over the next decade (2016-2026).

Scope

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global psoriatic arthritis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4
  • 1.4 Upcoming Related Reports 5

2. Executive Summary 6

  • 2.1 Key Findings 7
  • 2.2 Key Events 8

3. Introduction 9

  • 3.1 Report Scope 10
  • 3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

  • 4.1 Pipeline Overview 15
  • 4.2 Pipeline Breakdown by Region/Country 17
  • 4.3 Pipeline Breakdown by Molecule Type and Target 18
  • 4.4 Drug Review Designations 19
  • 4.5 Products in Early-Stage Clinical Development 20

5. Clinical Trial Assessment 21

  • 5.1 Clinical Trials Overview 22
  • 5.2 Top Sponsors of Clinical Trials in Psoriatic Arthritis 23
  • 5.3 Trial Breakdown by Region 25
  • 5.4 Therapy Area Perspective 26
  • 5.5 Enrollment Analytics 27

6. Commercial Assessment 30

  • 6.1 Leading Marketed Products 31
  • 6.2 Current & Future Players 32

7. Competitive Landscape Analysis (2016-2026) 33

  • 7.1 Events Classification Overview 34
  • 7.2 US 35
  • 7.3 5EU 36
  • 7.4 Japan 37
  • 7.5 Australia 38

8. Appendix 39

  • 8.1 Sources 40
  • 8.2 Methodology 41
  • 8.3 Key Events Included in the Analysis 42
  • 8.4 About the Authors 43
  • 8.5 About GlobalData 46
  • 8.6 Disclaimer 48